drugset / Trial / NCT07105176
HS-IT101 Injection for Advanced NSCLC
NaSingle-groupOpen-labelTreatment
Summary
An Open-Label, Single-Arm Phase Ib Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HS-IT101 Injection in Subjects with Advanced NSCLC.
Timeline
- Start
- 2025-08-30
- Primary completion
- 2026-08-30
- Completion
- 2027-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-IT101 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | IL-2 | Protein / enzyme biologic | — | Subcutaneous |